WO2021015515A1 - Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif - Google Patents
Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif Download PDFInfo
- Publication number
- WO2021015515A1 WO2021015515A1 PCT/KR2020/009533 KR2020009533W WO2021015515A1 WO 2021015515 A1 WO2021015515 A1 WO 2021015515A1 KR 2020009533 W KR2020009533 W KR 2020009533W WO 2021015515 A1 WO2021015515 A1 WO 2021015515A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture
- strain
- fatty liver
- preventing
- liver disease
- Prior art date
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 241000186191 Pediococcus inopinatus Species 0.000 title claims abstract description 31
- 239000004480 active ingredient Substances 0.000 title claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 12
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 239000003674 animal food additive Substances 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 14
- 239000012141 concentrate Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 8
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 8
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- 210000005228 liver tissue Anatomy 0.000 claims description 5
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 25
- 210000004185 liver Anatomy 0.000 abstract description 21
- 230000001965 increasing effect Effects 0.000 abstract description 19
- 235000009200 high fat diet Nutrition 0.000 abstract description 17
- 238000010171 animal model Methods 0.000 abstract description 13
- 230000014509 gene expression Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 201000007270 liver cancer Diseases 0.000 abstract description 9
- 208000014018 liver neoplasm Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 238000009825 accumulation Methods 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 2
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 25
- 241000192001 Pediococcus Species 0.000 description 20
- 239000003925 fat Substances 0.000 description 11
- 235000019197 fats Nutrition 0.000 description 11
- 235000021588 free fatty acids Nutrition 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 235000008504 concentrate Nutrition 0.000 description 8
- 229940049964 oleate Drugs 0.000 description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 6
- 241000320380 Silybum Species 0.000 description 6
- 235000010841 Silybum marianum Nutrition 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 101150065105 Cidec gene Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 235000021109 kimchi Nutrition 0.000 description 4
- 230000006372 lipid accumulation Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102100032137 Cell death activator CIDE-3 Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000775558 Homo sapiens Cell death activator CIDE-3 Proteins 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241000191996 Pediococcus pentosaceus Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000010150 least significant difference test Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102100038026 DNA fragmentation factor subunit alpha Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000950906 Homo sapiens DNA fragmentation factor subunit alpha Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 238000000719 MTS assay Methods 0.000 description 1
- 231100000070 MTS assay Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000011201 multiple comparisons test Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to a composition for preventing, improving or treating fatty liver disease comprising Pediococcus inofinatus as an active ingredient.
- liver disease in Korea is very high at 23.5 per 100,000 people, and is the number one cause of death in their 40s (41.1 people/10,000 people), the second cause of death in their 50s (72.4 people/10 million), and the third cause of death in their 30s.
- Liver disease, accounting for (10/10,000) is a major cause of death in the middle-aged Korean population.
- fatty liver refers to a phenomenon in which triglycerides, which are not present in normal cells, are abnormally excessively deposited in liver cells. About 5% of normal liver is composed of adipose tissue, and triglycerides, fatty acids, phospholipids, cholesterol and cholesterol esters are the main components of fat, but once fatty liver occurs, most of the components are replaced by triglycerides and the amount of triglycerides is reduced. Fatty liver is diagnosed if it is more than 5% of the weight of the liver.
- the fatty liver deteriorates and the fat mass in the hepatocyte becomes large, the important components of the cells including the nucleus are pushed to one side and the function of the hepatocyte decreases, and the expanded hepatocytes due to the accumulated fat in the cells press the microvessels and lymph glands between the hepatocytes. Thus, the circulation of blood and lymph fluid in the liver is impaired. In this case, the liver cells cannot properly receive oxygen and nutrients, and liver function is degraded.
- Non-alcoholic fatty liver disease is defined as a case where fatty acids accumulate more than 5% in the parenchymal cells of the liver in the form of triglycerides, not liver damage caused by alcohol. Pathologically, it is classified into simple steatosis and steatohepatitis with inflammation. If left untreated for a long time, it can lead to serious liver diseases such as hepatitis, liver fibrosis, and cirrhosis. In Korea, the incidence of non-alcoholic liver disease is also increasing due to lifestyle changes.
- alcoholic fatty liver occurs due to excessive drinking. Although there is a difference according to genetic characteristics and sex for each individual, liver disease such as alcoholic fatty liver is likely to occur when ingesting more than 80 g of alcohol per day. Women are more likely to develop alcoholic liver disease even in smaller doses. In general, it can be calculated that about 10g of alcohol is contained in 1 soju, 1 beer, 1 Western liquor, and 1 hop of makgeolli. Most of the symptoms are asymptomatic in patients with alcoholic fatty liver, which is the mildest form, but mild tenderness in the right upper abdomen can be complained of when mild hepatic hypertrophy (the liver is larger than normal).
- a probiotic composition including Pediococcus pentosaceus KID7 strain having a cholesterol-lowering effect is disclosed in Korean Patent No. 1673450, and Korean Patent No. 1611829 discloses obesity and obesity.
- the Pediococcus pentosaceus CBT SL4 strain and a composition containing the same are disclosed for the prevention or treatment of metabolic diseases, the prevention, improvement or prevention of fatty liver disease comprising Pediococcus inofinatus of the present invention as an active ingredient No therapeutic composition has been disclosed.
- the present invention is derived from the above requirements, the present invention provides a composition for the prevention, improvement or treatment of fatty liver disease comprising Pediococcus inofinatus as an active ingredient, the Pediococcus inofinatus Liver cancer cell line (HepG 2 ) has no cytotoxicity, effectively reduces the accumulation of triglycerides, reduces the content of ALT and TG in the blood in an animal model in which alcoholic fatty liver is induced, and animals in which fatty liver is induced through a high fat diet
- the present invention was completed by confirming that the model has the effect of lowering the ALT level, reducing the liver weight, and reducing the expression level of a fat metabolism-related gene in the liver.
- the present invention Pediococcus inopinatus ( Pediococcus inopinatus) WiKim0108 strain (Accession No: KACC 81091BP), the culture of the strain, the concentrate of the culture, the dried product of the culture and the extract of the culture It provides a health functional food composition for preventing or improving fatty liver disease comprising at least one selected from among the active ingredients.
- Pediococcus inopinatus WiKim0108 strain (accession number: KACC 81091BP), at least one selected from the culture of the strain, the concentrate of the culture, a dried product of the culture and an extract of the culture It provides a pharmaceutical composition for preventing or treating fatty liver disease comprising as an active ingredient.
- Pediococcus inopinatus WiKim0108 strain (accession number: KACC 81091BP), at least one selected from the culture of the strain, the concentrate of the culture, a dried product of the culture and an extract of the culture It provides a feed additive for preventing or improving fatty liver disease comprising as an active ingredient.
- Pediococcus inopinatus Pediococcus inopinatus
- WiKim0108 strain accession number: KACC 81091BP
- at least one selected from the culture of the strain the concentrate of the culture, a dried product of the culture and an extract of the culture
- KACC 81091BP accession number: KACC 81091BP
- the present invention relates to a composition for preventing, improving or treating fatty liver disease comprising Pediococcus inofinatus as an active ingredient, wherein Pediococcus inofinatus has no cytotoxicity in liver cancer cell line (HepG 2 ), and is neutral It has the effect of effectively reducing the accumulation of fat, lowering the blood ALT and TG content increased by alcohol, and lowering ALT levels in animal models in which fatty liver was induced through a high fat diet, reducing liver weight, and reducing fat in the liver. It has the effect of reducing the expression level of metabolic-related genes.
- N is a normal cell without any treatment.
- FIG. 3 is a result of treatment of the strain WiKim0108 in an animal model inducing alcoholic fatty liver and confirming the change in blood ALT content (A) and the change in TG content (B).
- ## indicates that the blood ALT and TG content in the vehicle group was statistically significantly increased compared to the normal group, p ⁇ 0.01, and * is the Pediococcus inofinatus strain of the present invention compared to the vehicle group, or Milk C, a positive control
- the blood ALT and TG contents in the knee treatment group were statistically significantly reduced, p ⁇ 0.05.
- ALT and AST are indicators of liver function.
- ## indicates that the content of ALT and AST in the blood of the high fat diet group (Veh) was statistically significantly increased compared to the normal group (N), p ⁇ 0.01.
- * Indicates that the ALT content in the blood of the group administered with Pediococcus inofinatus strain (WiKim0108) was statistically significantly reduced compared to the high fat diet group (Veh), p ⁇ 0.05.
- liver weight (A) and morphological change (B) after administration of Pediococcus inofinatus strain to an experimental animal ## indicates that the liver weight of the high fat diet group (Veh) was statistically significantly increased compared to the normal group (N), p ⁇ 0.01. *, ** indicates that the liver weight of the positive control group and the Pediococcus inofinatus strain (WiKim0108) administration group was statistically significantly reduced compared to the high fat diet group (Veh), * indicates p ⁇ 0.05, ** indicates p ⁇ Is 0.01.
- CIDEC cell death-inducing DFFA-like effector C
- the present invention is effective in one or more selected from Pediococcus inopinatus WiKim0108 strain (Accession No.: KACC 81091BP), culture of the strain, concentrate of the culture, dried product of the culture, and extract of the culture It relates to a health functional food composition for preventing or improving fatty liver disease comprising as an ingredient.
- the Pediococcus Inofinatus WiKim0108 strain is preferably isolated from skateboard or skate kimchi, but is not limited thereto.
- the extraction solvent of the extract of the Pediococcus inofinatus WiKim0108 strain culture is preferably water, a lower alcohol of C 1 to C 4 , or a mixture thereof, but is not limited thereto.
- the fatty liver disease is non-alcoholic or alcoholic simple fatty liver; Non-alcoholic or alcoholic steatohepatitis; And non-alcoholic or alcoholic cirrhosis, but is not limited thereto.
- the active ingredient is characterized by reducing the content of triglycerides in liver tissue, but is not limited thereto.
- the active ingredient is preferably prepared in any one formulation selected from powder, granule, pill, tablet, capsule, candy, syrup, and beverage, but is not limited thereto.
- the strain or a culture solution thereof may be added as it is, or may be used with other foods or food ingredients, and may be appropriately used according to a conventional method. have.
- the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
- the health functional food composition of the present invention may further include ingredients that are commonly added at the time of food production and are food wise acceptable.
- ingredients that are commonly added at the time of food production and are food wise acceptable For example, when prepared as a beverage, it may further include one or more components from citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, etc. in addition to the strain of the present invention.
- the amount that can be included as an active ingredient of the health functional food composition according to the present invention may be appropriately selected according to the age, sex, weight, condition, and symptoms of the disease of a person who wants a functional food for preventing or improving fatty liver disease It is recommended to contain about 0.01 to 10.0g per day for adults, and by ingesting foods having such a content, the effect of preventing or improving fatty liver disease can be obtained.
- Pediococcus inopinatus Pediococcus inopinatus
- WiKim0108 strain accession number: KACC 81091BP
- at least one selected from the culture of the strain the concentrate of the culture, a dried product of the culture and an extract of the culture
- KACC 81091BP accession number: KACC 81091BP
- the pharmaceutical composition may further include at least one selected from suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions.
- suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions.
- the pharmaceutical compositions according to the present invention are formulated in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to a conventional method. Can be used.
- Carriers, excipients and diluents that can be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, Various compounds or mixtures including calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. .
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, in the strain or the endoplasmic reticulum derived from the strain. , Sucrose (sucrose) or lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc.
- various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included.
- Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
- As a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
- the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount, and the term'pharmaceutically effective amount' of the present invention is sufficient to prevent or treat a disease at a reasonable benefit/risk ratio applicable to medical prevention or treatment. It means an amount, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the time of administration of the composition of the present invention used, the route of administration and the rate of excretion, treatment The duration, factors including drugs used in combination or co-use with the composition of the present invention used, and other factors well known in the medical field.
- the pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered single or multiple. Considering all of the above factors, it is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects.
- the frequency of administration of the composition of the present invention is not particularly limited thereto, but may be administered once a day or divided into several doses.
- the above dosage does not in any way limit the scope of the present invention.
- the term "individual" of the present invention includes, without limitation, mammals including mice, livestock, humans, etc. that are likely to develop fatty liver disease.
- the route of administration of the pharmaceutical composition may be administered through any general route as long as it can reach the target tissue.
- the pharmaceutical composition of the present invention is not particularly limited thereto, but may be administered through a route such as oral administration or rectal administration, and in some cases, may be administered by other routes depending on the purpose.
- the oral composition should be coated with an active agent or formulated to protect it from degradation in the stomach.
- the composition can be administered by any device capable of moving the active substance to the target cell.
- Pediococcus inopinatus Pediococcus inopinatus
- WiKim0108 strain accession number: KACC 81091BP
- at least one selected from the culture of the strain the concentrate of the culture, a dried product of the culture and an extract of the culture
- KACC 81091BP accession number: KACC 81091BP
- the feed additive of the present invention corresponds to an auxiliary feed in the feed management method.
- the term'feed' may mean any natural or artificial diet, one meal meal, etc., or a component of the one meal meal for animals to eat, ingest, and digest.
- the kind of feed is not particularly limited, and feeds commonly used in the art may be used.
- Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, meals or grain by-products; Animal feeds such as proteins, inorganic logistics, oils and fats, minerals, oils and fats, single-cell proteins, zooplanktons or foods. These may be used alone or in combination of two or more.
- the present invention Pediococcus inopinatus ( Pediococcus inopinatus) WiKim0108 strain (accession number: KACC 81091BP), at least one selected from the culture of the strain, the concentrate of the culture, a dried product of the culture and an extract of the culture It relates to a veterinary composition for preventing or treating fatty liver disease in animals other than humans comprising as an active ingredient.
- liver cancer cell line (HepG 2 )
- the liver cancer cell line (HepG 2 ) was purchased and used from ATCC (American Type Culture Collection).
- the liver cancer cell line (HepG 2 ) was cultured in DMEM-F12 (Dulbecco's modified Eagle's medium) medium containing 10% FBS and 1% penicillin-striptomycin.
- the cells were cultured in a 5% CO 2 incubator at 37°C, and the cultured cells were tested by dispensing a constant number of cells (1 ⁇ 10 5 cells/500 ⁇ l well) into a 24-well plate. After dispensing the cells in a 24-well plate, the cells were completely attached to the 24-well plate to form a cell shape, and the cells were used when they reached 75% confluence.
- the 100mM palmitate and 100mM oleate stock solutions prepared in (1) above were 165 ⁇ l (1.65mM) of palmitate and 330 ⁇ l (3.3mM) of oleate, and 9,505 ⁇ l of 5% ( w/v) BSA solution was shaken while dropping and mixing (vortexing). Thereafter, it was cooled to room temperature, and then filtered through a 0.2 ⁇ m filter (the prepared mixed solution is stable even if stored at -20°C for 3 to 4 weeks).
- the drug was orally administered to each group once a day for 12 days from the 3% alcohol diet, the normal group was administered DW for SPF, the vehicle group was administered saline, and the Pediococcus inofinatus strain (WiKim0108) was administered. Silver Pediococcus inofinatus strain was administered in an amount of 3 ⁇ 10 8 CFU per head, and the milk thistle administration group was administered with 50 mg/kg of milk thistle as a positive control.
- the new strain used in the present invention takes skate kimchi (10g) purchased from the Skate Farming Association in Youngsanpo, Naju, Jeollanam-do, diluted with sterilized physiological saline, spread on a solid medium for separating MRS lactic acid bacteria, and incubated at 30°C for 48 hours. Different microorganisms were separated and used according to the type of colony. The isolated microorganisms were cultured at 30° C. for 48 hours in minimal nutrient medium (1% glucose, 0.5% yeast extract).
- the skate kimchi microorganism WiKim0108 was identified through 16S ribosomal DNA gene sequence analysis. After taking the cells of the selected microorganism and washing the cells twice in sterilized physiological saline, DNA was extracted using a DNeasy tissue kit (Qiagen, Valecia, CA, USA). Universal primer for amplifying the 16S ribosomal DNA gene of the extracted DNA; 27F (5'-AGAGTTTGATCATGGCTCAG-3') (SEQ ID NO: 1) and 1492R (5'-GGATACCTTGTTACGACTT-3') (SEQ ID NO: 2) primers were used.
- PCR reaction in 10 ⁇ l of Takara Perfect Premix (Takara, Japan) containing 0.4mM dNTP, 0.5 unit of Taq polymerase, 4mM Mg 2+ , 1 ⁇ l of DNA template (20 ⁇ g/ml), 1.0 ⁇ M forward primer 1.0 ⁇ M reverse primer was added to each 1 ⁇ l, and distilled water was added to the remainder to give a total volume of 20 ⁇ l.
- PCR amplification was performed with a Mastercycler gradient (Eppendorf, Hamburg, Germany). The PCR reaction was performed at 95°C for 5 minutes (initial denaturation), 94°C for 45 seconds (denaturation), 52°C for 45 seconds (annealing), 72°C for 1 minute (extension), 30 cycles, and 72°C for 5 minutes. The final extension was carried out for minutes.
- the amplified fragment of about 1400bp was transformed after binding to a T vector (Invitrogen, Carlsbad, CA, USA).
- the new strain WiKim0108 was 97% consistent with the Pediococcus inopinatus standard strain BT (SEQ ID NO: 3). Subsequently, the new strain was named Pediococcus inopinatus WiKim0108 ( Pediococcus inopinatus WiKim0108). In addition, the Pediococcus Inofinatus WiKim0108 was deposited with the Agricultural Genetic Resource Center of the National Academy of Agricultural Sciences on March 8, 2019, and was given the deposit number KACC 81091BP.
- the cultured HepG 2 cells were diluted by concentration for 24 hours and treated, and MTS assay (CellTiter Aqueous One Solution Cell proliferation assay kit, 3-(4,5-dimethylthiazol-2-yl)-5-(3) -carboxymethoxyphenyl)-2-(4-sulfophynyl)-2H-tetrazolium, inner salt; MTS, Promega Co.Madison, WI, USA) to determine cell viability at 490nm by microplate reader (Molecular Devices, Sunnyvale, CA, USA) It was measured as.
- MTS assay CellTiter Aqueous One Solution Cell proliferation assay kit, 3-(4,5-dimethylthiazol-2-yl)-5-(3) -carboxymethoxyphenyl)-2-(4-sulfophynyl)-2H-tetrazolium, inner salt; MTS, Promega Co.Madison, WI, USA
- the cell survival rate (%) when the WiKim0108 strain of the present invention was treated was approximately similar to that of the normal group (N). Therefore, it was found that the WiKim0108 strain of the present invention had little cytotoxicity.
- liver cancer cell line HepG 2
- the increased lipid accumulation was reduced by the treatment of the WiKim0108 strain by treating the prepared 1 mM oleate and palmitate mixture (2:1) free fatty acid.
- the blood ALT content in the vehicle group administered with alcohol compared to the normal group was significantly increased as disclosed in FIG. 3(A)
- the blood ALT content of the milk thistle administration group (positive control group) and the WiKim0108 administration group was significantly decreased.
- the TG content in the blood in the vehicle group administered with alcohol compared to the normal group was increased, as disclosed in FIG.
- the blood TG content of the WiKim0108-administered group was significantly decreased compared to the vehicle group with increased TG content.
- mice Six-week-old male C57BL/6J mice were purified, followed by ingestion of a 60 kcal% fat diet (D12492, Research Diet, Inc) to induce non-alcoholic fatty liver. When the average body weight reached 28-29g, the WiKim0108 strain was administered orally for 10 weeks (1 ⁇ 10 8 , 1 ⁇ 10 9 CFU/mice/day), and the body weight was measured weekly, and as a positive control, milk thistle (MT, 100mg/kg/day) was administered.
- MT milk thistle
- the weight of the high fat diet group (HFD) increased compared to the normal group, and in contrast, the weight of the WiKim0108 strain administration group and the milk thistle administration group (MT) of the present invention decreased slightly. I did.
- Example 5 the content of ALT and AST, which are indicators of liver function, in blood (serum) collected from the animal model by cardiac puncture was measured.
- the ALT and AST content in the blood of the high fat diet group (Veh) compared to the normal group (N) was statistically significantly increased, and Pediococcus inofinatus compared to the high fat diet group (Veh)
- the ALT content in the blood of the strain (WiKim0108) administration group was statistically significantly reduced.
- Example 6 the experimental animals were sacrificed and the weight and morphological changes were confirmed after liver tissue extraction.
- the liver weight of the high fat diet group (HFD) increased compared to the normal group, and in contrast, the liver weight of the WiKim0108 strain administration group and the milk thistle administration group (MT) of the present invention was increased. It was confirmed that there was a statistically significant decrease.
- the morphological change of the liver was confirmed as disclosed in FIG. 6(B), and the liver of the high fat diet group (Veh) became enlarged compared to the normal group (N), and the liver of the WiKim0108 strain administration group of the present invention compared to the high fat diet group It was confirmed that the shape was similar to that of the normal group.
- RNA was isolated from a sample of 30 mg of liver tissue obtained in Example 7, and cell death-inducing DFFA (CIDEC) related to lipid droplets involved in the regulation of fat metabolism through reverse transcription and Q-PCR using Taqman probe (ABI). -like effector C) relative mRNA expression levels were confirmed.
- CIDEC cell death-inducing DFFA
- the CIDEC gene expression level of the high fat diet group (Veh) was statistically significantly increased compared to the normal group (N), and the positive control group and Pediococcus inofina compared to the high fat diet group (Veh)
- the amount of CIDEC gene expression in the group administered with the tooth strain (WiKim0108) was statistically significantly reduced.
- Example 2 of the present invention were tested for significance between the control and the control group by performing the LSD test using the SPSS ver 20.0 program.
- Example 3 The results obtained in Example 3 were expressed as the mean ⁇ standard error of the mean (SEM), for statistical analysis, ANOVA was performed in GraphPad Prism 8.1.2, and for post-mortem analysis, the significance was tested by performing Dunnett's multiple comparisons test.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une composition pour prévenir, améliorer ou traiter la stéatose hépatique, la composition comprenant du Pediococcus inopinatus en tant que principe actif. Spécifiquement, le Pediococcus inopinatus ne présente pas de cytotoxicité et a également pour effet de réduire efficacement l'accumulation de graisse neutre dans une lignée cellulaire de cancer du foie (HepG2), de réduire le taux d'ALT et de TG, renforcé par l'alcool, dans le sang, d'abaisser les taux d'ALT dans un modèle animal chez lequel une stéatose hépatique a été induite par un régime riche en graisses, de réduire le poids du foie, et de réduire le niveau d'expression d'un gène associé au métabolisme des lipides dans le foie et, ainsi, la composition de la présente invention peut être utilisée utilement en tant qu'aliment fonctionnel de santé, médicament, additif alimentaire ou composition vétérinaire pour prévenir, améliorer ou traiter la stéatose hépatique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190087438 | 2019-07-19 | ||
KR10-2019-0087438 | 2019-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021015515A1 true WO2021015515A1 (fr) | 2021-01-28 |
Family
ID=74192655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/009533 WO2021015515A1 (fr) | 2019-07-19 | 2020-07-20 | Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102406639B1 (fr) |
WO (1) | WO2021015515A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101617141B1 (ko) * | 2015-03-03 | 2016-05-02 | 한국식품연구원 | 항비만 활성을 갖는 페디오코쿠스 이노피나투스 |
KR101660272B1 (ko) * | 2009-02-27 | 2016-09-27 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | 비만예방 또는 개선제 |
KR20180049732A (ko) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
KR20180049731A (ko) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
JP2018191638A (ja) * | 2017-05-18 | 2018-12-06 | セル バイオテック カンパニー リミテッド | アルコールまたはアセトアルデヒド分解用プロバイオティクスを含む組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5801802B2 (ja) | 2010-06-08 | 2015-10-28 | カルピス株式会社 | 脂質代謝改善剤 |
KR102158667B1 (ko) | 2019-05-09 | 2020-09-22 | 한국 한의학 연구원 | 면역기능 조절 및 염증성 장질환의 개선효과를 갖는 페디오코쿠스 이노피나투스 WiKim0108 균주 및 이의 용도 |
-
2020
- 2020-07-20 WO PCT/KR2020/009533 patent/WO2021015515A1/fr active Application Filing
- 2020-07-20 KR KR1020200089672A patent/KR102406639B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101660272B1 (ko) * | 2009-02-27 | 2016-09-27 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | 비만예방 또는 개선제 |
KR101617141B1 (ko) * | 2015-03-03 | 2016-05-02 | 한국식품연구원 | 항비만 활성을 갖는 페디오코쿠스 이노피나투스 |
KR20180049732A (ko) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
KR20180049731A (ko) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
JP2018191638A (ja) * | 2017-05-18 | 2018-12-06 | セル バイオテック カンパニー リミテッド | アルコールまたはアセトアルデヒド分解用プロバイオティクスを含む組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR102406639B1 (ko) | 2022-06-10 |
KR20210010420A (ko) | 2021-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021137603A1 (fr) | Souche de lactobacillus plantarum, et composition pour la prévention ou le traitement des maladies métaboliques la contenant | |
WO2017082611A1 (fr) | Souche ayant la capacité d'inhiber l'obésité et composition pharmaceutique la contenant | |
WO2019199094A1 (fr) | Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante | |
WO2020091166A1 (fr) | Nouvelles bactéries lactiques et leur utilisation | |
CN112930392A (zh) | 用于上呼吸道感染、压力、焦虑、记忆和认知功能障碍和衰老的益生菌 | |
WO2021137602A1 (fr) | Souche de lactobacillus fermentum, et composition pour la prévention ou le traitement de maladies métaboliques, comprenant celle-ci | |
WO2018043864A1 (fr) | Souche de leuconostoc holzapfelii ayant pour effets de prévenir la perte des cheveux, de favoriser la pousse des cheveux ou d'améliorer la fonction sexuelle, et composition la comprenant | |
WO2021015514A1 (fr) | Composition comprenant enterococcus lactis en tant que principe actif pour la prévention, le soulagement, ou le traitement de la stéatose hépatique | |
WO2018090983A9 (fr) | Composé de saponine pour améliorer la microflore intestinale, son procédé de préparation et son utilisation | |
WO2020076043A1 (fr) | Bactéries du microbiote intestinal présentant un effet prophylactique ou thérapeutique contre la dépression, et utilisation correspondante | |
WO2020226468A1 (fr) | Souche de pediococcus inopinatus wikim0108 ayant un effet de régulation de la fonction immunitaire et de soulagement d'une maladie intestinale inflammatoire et son utilisation | |
WO2020226467A1 (fr) | Souche d'enterococcus lactis wik0107 ayant des effets de régulation des fonctions immunitaires et d'atténuation des maladies inflammatoires chroniques intestinales et son utilisation | |
WO2021172900A1 (fr) | Souche de lactobacillus helveticus et composition la contenant pour la prévention ou le traitement de maladies inflammatoires | |
WO2021015515A1 (fr) | Composition pour prévenir, améliorer ou traiter la stéatose hépatique, comprenant du pediococcus inopinatus comme principe actif | |
WO2020045972A1 (fr) | Souche de lactobacillus fermentum mg4231 ou de lactobacillus fermentum mg4244 dérivé du corps humain, ayant une activité anti-obésité, et composition la comprenant | |
KR20210014605A (ko) | 간 손상 예방, 개선, 또는 치료용 조성물 | |
WO2022139489A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement d'une stéatose hépatique alcoolique et non alcoolique | |
WO2019117616A1 (fr) | Composition comprenant une souche d'agathobaculum sp. en tant que principe actif pour la prévention, l'atténuation ou le traitement d'un trouble du spectre autisitique | |
EP4356918A1 (fr) | Utilisation d'une souche de lactobacillus fermentum et de lymphocytes t régulateurs en polythérapie pour la prévention et le traitement d'une maladie métabolique | |
WO2022260335A1 (fr) | Composition pour améliorer la population microbienne intestinale comprenant du galactose | |
WO2023058801A1 (fr) | Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409 | |
WO2021020923A1 (fr) | Composition pour prévenir, soulager ou traiter une lésion hépatique | |
WO2021125822A1 (fr) | Composition destinée à soulager la gueule de bois, contenant du pediococcus inopinatus comme principe actif | |
WO2019164197A1 (fr) | Nano-vésicules dérivées de bactéries catenibacterium et utilisation associée | |
WO2019156335A1 (fr) | Composition pharmaceutique destinée au traitement de la stéatose hépatique et aliment fonctionnel de santé destiné à l'amélioration de la fonction hépatique, les deux contenant un extrait ou une poudre de pleurotus eryngii var. ferulae en tant que principe actif |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20843088 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20843088 Country of ref document: EP Kind code of ref document: A1 |